Grazoprevir/elbasvir treatment for the relapse of HCV genotype 1b infection after ledipasvir/sofosbuvir: A case report

The treatment of chronic hepatitis C has radically changed due to the development of direct-acting antiviral agents (DAAs). Twelve-week treatment with ledipasvir and sofosbuvir (LDV/SOF), a combination of DAAs, is highly effective in patients with hepatitis C virus (HCV) genotype 1 infection. Howeve...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Exp Ther Med
Autors principals: Tadokoro, Tomoko, Morishita, Asahiro, Oura, Kyoko, Fujita, Koji, Mimura, Shima, Sakamoto, Teppei, Nomura, Takako, Tani, Joji, Yoneyama, Hirohito, Masaki, Tsutomu
Format: Artigo
Idioma:Inglês
Publicat: D.A. Spandidos 2018
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6090207/
https://ncbi.nlm.nih.gov/pubmed/30116355
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2018.6207
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars